Fig. 1
From: TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma
Schematic diagram of the study. All patients provided informed consent to collecting T-cell lymphoma (TCL) in situ tumor tissue, plasma, or peripheral blood mononuclear cells (PBMCs) for deoxyribonucleic acid (DNA) extraction. Then, the prepared DNA was subjected to exome sequencing for bioinformatics analysis or polymerase chain reaction (PCR) and Sanger sequencing for comparison with healthy individual (HI) sequences, which identified the variant sites and types of TNFAIP3 mutations. Finally, the clinical information of the TCL patients was collected for prognostic analysis, and the TNFAIP3 mutation data from Jinan University (JNU) and Guangdong Provincial People’s Hospital (GDPH) were compared to those in the Catalogue of Somatic Mutations in Cancer (COSMIC)  and Gene Expression Omnibus (GEO) databases